Bispecific antibody

Show results for

Unknown (1700)
Genomics (81)
Transcriptomics (55)
Proteomics (26)
Clinical (22)
Metabolomics (2)
Other (1)
Methylation profiling (1)

Organisms

Homo sapiens (35)
Mus musculus (27)
Mycobacterium tuberculosis SP7 (16)
Mycobacterium tuberculosis SP10 (16)
Mycobacterium tuberculosis SP13 (16)
Mycobacterium tuberculosis SP22 (16)
Chlamydomonas reinhardtii (16)
Enterococcus mundtii CRL35 (16)
Oncorhynchus tshawytscha (16)
Pseudomonas canadensis (16)
Human alphaherpesvirus 1 strain 17 (16)
Mycobacterium tuberculosis SP1 (16)
Marchantia polymorpha subsp. ruderalis (16)
Methylocystis sp. (16)
Exiguobacterium sp. SH31 (16)
Palaemonetes sp. common grass shrimp associated circular virus (16)
Amaranthus tricolor (16)
Clavibacter nebraskensis NCPPB 2581 (16)
Porites pukoensis (16)
Porphyromonas gingivalis (16)
Porphyromonas gingivalis W83 (16)
Human betaherpesvirus 5 (16)
Bothrops insularis (16)
Bothrops jararaca (16)
Bothrops jararacussu (16)
Saccharomyces cerevisiae (2)
Schizosaccharomyces pombe (1)
Rattus norvegicus (1)
Arabidopsis thaliana (1)
Danio rerio (1)

Organisms

Homo sapiens (27)
Mus musculus (23)
Danio rerio (1)

Repository

ENA (73)
geo (48)
pride (16)
biostudies-arrayexpress (12)
MassIVE (8)
EGA (5)
MetaboLights (2)
iProX (1)
PanoramaPublic (1)

Tissue

Cell culture (6)
Liver (2)
Bone (1)
Peripheral blood mononuclear cell (1)
Bone marrow (1)
Permanent cell line cell (1)
B cell (1)
Blood serum (1)
Colon (1)
Lung (1)
Blood plasma (1)
Kidney (1)
Epithelial cell (1)
Hepatocyte (1)

Disease

Colorectal Neoplasms (12)
Lung Neoplasms (2)
Carcinoma (2)
Neoplasms, Glandular and Epithelial (1)
Gastric cancer (1)
Head and Neck Neoplasms (1)
Carcinoma, Renal Cell (1)
Colorectal cancer (1)
Neoplasms (1)
Alveolar rhabdomyosarcoma (1)
Rhabdomyosarcoma (1)
Embryonal rhabdomyosarcoma (1)
Melanoma (1)
Chronic lymphocytic leukemia (1)
Chronic kidney disease (1)

Technology Type

Mass Spectrometry (16)
Affinity purification coupled with mass spectrometry proteomics (4)
Shotgun proteomics (4)
Bottom-up proteomics (3)
Top-down proteomics (3)
Data-dependent acquisition (3)
Gel-based experiment (2)
Mass spectrometry (1)
Mass spectrometry assay (1)
Mass spectrometry imaging (1)

Instrument Platform

Orbitrap Fusion Lumos (2)
Thermo Q-Exactive HF (QE) Quadrupole-Obitrap mass spectrometer (1)
Q-Exactive HF (QE) Quadrupole-Obitrap mass spectrometer (1)
Orbitrap Ascend (1)
LTQ (1)
Orbitrap Exploris 480 (1)
Q Exactive Plus (1)
MS Imaging - negative (1)
Liquid Chromatography MS - negative - reverse phase (1)

Publication Date

2026 (19)
2025 (14)
2023 (10)
2024 (8)
2022 (8)
2021 (7)
2020 (7)
2017 (4)
2013 (3)
2012 (2)
2014 (1)
2011 (1)
2010 (1)
2006 (1)
2027 (1)
2019 (1)

CHEBI ID

CHEBI:183110 (1)
CHEBI:183108 (1)
CHEBI:183106 (1)
CHEBI:178065 (1)
CHEBI:31011 (1)
CHEBI:16135 (1)
CHEBI:28484 (1)
CHEBI:37070 (1)
CHEBI:30768 (1)
CHEBI:9907 (1)
CHEBI:16525 (1)
CHEBI:30772 (1)
CHEBI:28865 (1)
CHEBI:16325 (1)
CHEBI:9410 (1)
CHEBI:28834 (1)
CHEBI:16359 (1)
CHEBI:80774 (1)
CHEBI:15366 (1)

Metabolite Name

Ursodeoxycholic Acid-D4 (1)
Tauroursodeoxycholic acid-D4 (1)
Taurodeoxycholic acid-D4 (1)
Taurocholic Acid-D4 (1)
Taurochenodeoxycholic Acid-D4 (1)
Lithocholic Acid-D4 (1)
Deoxycholic Acid-D4 (1)
Cholic Acid-D4 (1)
Taurochenodeoxycholic Acid (1)
Lithocholic Acid (1)
Ursodeoxycholic Acid (1)
Deoxycholic Acid (1)
Cholic Acid (1)
Tauroursodeoxycholic acid (1)
Taurocholic Acid (1)
Taurodeoxycholic acid (1)

First Public Date

2026 (28)
2025 (9)
2024 (9)
2022 (8)
2021 (7)
2020 (6)
2023 (4)
2019 (1)
2017 (1)

Study status

Recruiting (9)
Not yet recruiting (5)
Completed (3)
Available (1)
Ongoing (1)
Withdrawn (1)
Terminated (1)
Not provided (1)

Study type

Interventional (20)
Transcription profiling by array (8)
ChIP-chip by tiling array (1)
Comparative genomic hybridization by array (1)
ChIP-seq (1)
RNA-seq of coding RNA (1)
Expanded access (1)
Other (1)

Release Date

2025 (252)
2022 (227)
2021 (217)
2023 (216)
2024 (212)
2020 (147)
2019 (78)
2018 (75)
2017 (74)
2016 (56)
2015 (45)
2026 (34)
2014 (27)
2013 (15)
2012 (15)
2011 (8)
2010 (7)
2009 (5)
2006 (1)
2008 (1)

Lab affiliation

University of Oxford; University of Utrecht (1)
Senior Principal Scientist I,Bioprocessing Technology Institute, A*Star, Singapore Adjunct Associate Professor, Duke-NUS Medical School, Singapore Adjunct Associate Professor,Singapore Institute of Technology, Singapore (1)
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland (1)
Department of Microbiology and Immunology, The Scripps Research Institute; Jupiter, FL, USA (1)
Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Canada (1)
School of Pharmacy, Engineering Research Center of Cell& Therapeutic Antibody, Ministry of Education,Shanghai Jiao Tong University (1)
Professor, Associate Director of Academic Affairs, Division of Hematology, Professor of Medicine, Dept of Internal Medicine (1)
Regeneron Pharmaceuticals, Tarrytown, NY (1)
Functional Genetics Division, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, UK (1)
Centre de recherche du Centre Hospitalier Universitaire (CHU) de Quebec-Université Laval, Québec, QC, Canada Centre de recherche sur le cancer de l’Université Laval, Québec, QC, Canada PROTEO-Quebec Network for Research on Protein Function, Engineering, and Applications, Québec, QC, Canada Department of Molecular Biology, Medical Biochemistry and Pathology, Université Laval, Québec, QC, Canada (1)
Institute of Bioengineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, China, 310027 (1)
Department of Chemistry, University of Washington, Seattle, WA, USA (1)
University of Oxford (1)
Core Facility for Mass Spectrometry and Proteomics, Center for Molecular Biology of Heidelberg University (ZMBH), DKFZ-ZMBH Alliance, 69120 Heidelberg, Germany (1)
Hubei University of Technology (1)
Massachusetts Institute of Technology (1)

Location

China (10)
United States (5)
Netherlands (2)
France (2)
Portugal (1)
United Kingdom (1)
Spain (1)
Italy (1)
Belgium (1)
Germany (1)

Keyword

Antibodies, Bispecific (4)
Bispecific antibody (4)
Antibodies (4)
Removab (1)
Early Access (1)
Compassionate use (1)
Expanded access (1)
New therapy (1)
Radioimmunotherapy (1)
Pretargeting (1)
Lutetium 177 (1)
Phase I clinical trial (1)
Urothelial Cancer (UC) (1)
Metastatic colorectal cancer (mCRC) (1)
Head and neck squamous cell carcinoma (HNSCC) (1)
Triple negative breast cancer (TNBC) (1)
Not assigned (1)
First-in-human (1)
MCLA-158 (1)
Bispecific (1)
Immunologic factors (1)
LGR5 (1)
PD-1 activated CIK (1)
MUC1 (1)
Renal cell carcinoma (RCC) (1)
Pancreas cancer (1)
PD-1 (1)
CTLA-4 (1)
Stage I rectal cancer (1)
Cytokines (1)

Previous page
1 / 189
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 189
Next page

Sort by:

Relevance

Page size

LC-MS characterization of anti-PD-L1 and CXCR4 bispecific nanobodies

Antibodies and derivative drugs targeting immune checkpoints have been approved for the treatment of several malignancies, but there are fewer responses in patients with pancreatic cancer. Here, we designed a nanobody molecule with bi-targeting on PD-L1 and CXCR4, as both targets are overexpressed i...

ORGANISM(S): Homo sapiens (Human)

2023-03-11 | PXD037102 | Pride

Tandem bispecific IL-7 receptor agonist antibody

PRJNA1327777 | ENA

An Unbiased Strategy for Selecting Effective Combinations of Therapeutic Targets Supports the Development of a Novel Bispecific Antibody with Tumor-Suppressing Properties

Recent progress in dissecting molecular mechanisms essential for the survival and propagation of cancer cells triggered rapid development of targeted therapies. Although many of these therapies produce impressive initial responses in tumor suppression, the onset of resistance is practically unavoida...

ORGANISM(S): Homo sapiens (Human)

2023-01-27 | PXD023034 | Pride

Bispecific anti-egfr/epha2 antibody epha2 receptor bioid proximity proteomics

A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy

PRJNA669680 | ENA

An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers.

Not available

S-EPMC8220303 | biostudies-literature

T-cell exhaustion induced by continuous bispecific antibody exposure is ameliorated by treatment-free intervals

PRJNA805096 | ENA

Targeting dendritic cells with a PD-L1 based bispecific antibody rejuvenates specific anti-tumor T cells

PRJNA887799 | ENA

A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy

CD3-bispecific antibodies represent an important therapeutic strategy in oncology. These molecules work by redirecting cytotoxic T cells to antigen-bearing tumor cells. Although CD3-bispecific antibodies have been developed for several clinical indications, cases of cancer-derived resistance are an ...

ORGANISM(S): Homo sapiens

2020-11-12 | GSE159547 | GEO

CLEC5a-directed bispecific antibody for effective cellular phagocytosis.

Not available

S-EPMC8932924 | biostudies-literature

Tandem bispecific IL-7 receptor agonist antibody

Interleukin-7 (IL-7) is essential for T cell immunity, but the therapeutic application of existing IL-7 therapies is limited by narrow therapeutic window and suboptimal pharmacokinetics. To address this, we engineered a fully human tandem bispecific antibody, TB4, that functions as a potent IL-7 rec...

ORGANISM(S): Homo sapiens

2026-06-29 | GSE307905 | GEO

Previous page
1 / 189
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 189
Next page

Sort by:

Relevance

Page size

1888 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Study status

Study type

Release Date

Lab affiliation

Location

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets